How much revenue does Shenzhen Chipscreen Biosciences make?

Shenzhen Chipscreen Biosciences reported 657.95 million CNY in revenue for fiscal year 2024, up 25.6% from 523.71 million CNY in fiscal year 2023. In Q2 2025 revenue was 244.33 million CNY.

Where does Shenzhen Chipscreen Biosciences make most of its revenue?

South China: 31% of revenue by region in fiscal year 2025, followed by East China (28%).

What companies are similar to Shenzhen Chipscreen Biosciences?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SS), Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS), Betta Pharmaceuticals Co., Ltd. (300558.SZ), InventisBio Co., Limited (688382.SS).

Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS) Stock

About Shenzhen Chipscreen Biosciences Co., Ltd.

Shenzhen Chipscreen Biosciences Co., Ltd. engages in the pharmaceutical industry in China. The company develops Chidamide, a subtype-selective histone deacetylase inhibitor for peripheral T-cell lymphoma, breast cancer, and diffuse large B-cell lymphoma indications; Chiglitazar, a PPAR full agonist for diabetes treatment; Siglitazone for metabolism treatment area; and Cioronib, a novel molecular, ...

At a glance

Shenzhen Chipscreen Biosciences reported revenue of 657.95 million CNY for fiscal year 2024, up 25.6% from fiscal year 2023, and net income of -114.57 million CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 244.33 million CNY, up 42.4% from a year before. South China was its largest region in fiscal year 2025, with 31% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.